Instrument Inactif

Autres langues NICOX Swiss Exchange

Actions

OXCOX

FR0000074130

Produits pharmaceutiques

Autres langues

01/07	Nicox Submits NCX 470 New Drug Application In The United States
01/07	Nicox’s NCX 470 New Drug Application Submitted in the United States by Kowa, with Associated €3 million Milestone Payment
23/06	Nicox Bags EUR6 Million Shareholder Loan
23/06	Nicox and Vester Finance Sign Shareholder Loan Agreement to Support Strategic Activities for the Company
18/06	Nicox Announces Positive Pre-Submission Regulatory Feedback in China Supporting NDA Filing for NCX 470
18/06	Nicox Announces Positive Pre-submission Regulatory Feedback in China Supporting NDA filing for NCX 470
08/06	Reminder: Nicox June 2024 Warrants will expire June 19, 2026
03/06	Nicox: Notice of the Ordinary and Extraordinary Shareholders’ Meeting on June 24, 2026 and appointment of an ad hoc representative
30/04	Nicox Provides Full Year 2025 Financial Results and Corporate Update
30/04	Nicox S.A. Reports Earnings Results for the Full Year Ended December 31, 2025
20/04	Reminder: Last Exercise Day for Nicox June 2024 Warrants is June 19, 2026
24/02	Nicox SA Highlights Positive NCX 470 Phase 3 Data Confirming Therapeutic Profile at the 2026 American Glaucoma Society Annual Meeting
24/02	Nicox Highlights Positive NCX 470 Phase 3 Data Confirming Therapeutic Profile at the 2026 American Glaucoma Society Annual Meeting
16/02	Nicox Announces Positive Feedback from pre-NDA Meeting with U.S. FDA for NCX 470
10/02	Nicox to Present Data from NCX 470 Phase 3 Studies at American Glaucoma Society (AGS) Annual Meeting 2026
20/01	Nicox Announces Conference Attendance in H1 2026 and Upcoming Scientific Data Presentations
05/01	Nicox Repays Debts to Kreos Capital, Extends Cash Runway
05/01	Nicox Announces Complete Repayment of Kreos Capital Debt and Extends Cash Runway Beyond 2027 with New Additional Financing
05/01	Nicox S.A. announced that it expects to receive ?4.000031 million in funding
16/12	Nicox Completes NCX 470 New Drug Application Key Data Generation for Submission as Planned in H1 2026
16/12	Nicox SA Completes NCX 470 New Drug Application Key Data Generation for Submission as Planned in First First 2026
23/10/25	Nicox S.A. Reports Earnings Results for the Half Year Ended June 30, 2025
23/10/25	Nicox Provides First Half 2025 Financial Results
03/10/25	Nicox's NCX 470 Demonstrates Sustained Efficacy through 12 Months in Denali Clinical Trial with no new Safety Observations
02/10/25	Nicox SA Completes the Additional Pre-Planded Analyses of the NCX 470 Denali Phase 3 Clinical Trial Data